Structural variation in the glycogen synthase kinase 3β and brain-derived neurotrophic factor genes in Japanese patients with bipolar disorders.
bipolar disorder
brain-derived neurotrophic factor
copy number variation
glycogen synthase kinase 3®
lithium
Journal
Neuropsychopharmacology reports
ISSN: 2574-173X
Titre abrégé: Neuropsychopharmacol Rep
Pays: United States
ID NLM: 101719700
Informations de publication
Date de publication:
03 2020
03 2020
Historique:
received:
09
08
2019
revised:
20
10
2019
accepted:
21
10
2019
pubmed:
27
11
2019
medline:
29
5
2021
entrez:
27
11
2019
Statut:
ppublish
Résumé
Lithium is the first-line drug for the treatment of bipolar disorders (BDs); however, not all patients responded. Glycogen synthase kinase (GSK) 3β and brain-derived neurotrophic factor (BDNF) play a role in the therapeutic action of lithium. Since structural variations were reported in these genes, it is possible that these genomic variations may be involved in the therapeutic responses to lithium. Fifty patients with BDs and 50 healthy subjects (mean age 55.0 ± 15.0 years; M/F 19/31) participated. We examined structural variation of the GSK3β and BDNF genes by real-time PCR. We examined the influence of structural variation of these genes on the therapeutic responses to lithium and the occurrence of antidepressant-emergent affective switch (AEAS). The efficacy of lithium was assessed using the Alda scale, and AEAS was evaluated using Young Mania Rating Scale. Although we examined structural variations within intron II and VII of the GSK3 The amplification of the BDNF gene influenced neither the therapeutic responses to lithium nor the occurrence of AEAS.
Sections du résumé
BACKGROUND
Lithium is the first-line drug for the treatment of bipolar disorders (BDs); however, not all patients responded. Glycogen synthase kinase (GSK) 3β and brain-derived neurotrophic factor (BDNF) play a role in the therapeutic action of lithium. Since structural variations were reported in these genes, it is possible that these genomic variations may be involved in the therapeutic responses to lithium.
METHOD
Fifty patients with BDs and 50 healthy subjects (mean age 55.0 ± 15.0 years; M/F 19/31) participated. We examined structural variation of the GSK3β and BDNF genes by real-time PCR. We examined the influence of structural variation of these genes on the therapeutic responses to lithium and the occurrence of antidepressant-emergent affective switch (AEAS). The efficacy of lithium was assessed using the Alda scale, and AEAS was evaluated using Young Mania Rating Scale.
RESULTS
Although we examined structural variations within intron II and VII of the GSK3
CONCLUSION
The amplification of the BDNF gene influenced neither the therapeutic responses to lithium nor the occurrence of AEAS.
Identifiants
pubmed: 31769621
doi: 10.1002/npr2.12083
pmc: PMC7292225
doi:
Substances chimiques
Antimanic Agents
0
Brain-Derived Neurotrophic Factor
0
Cytoskeletal Proteins
0
Lithium Compounds
0
NIN protein, human
0
Nuclear Proteins
0
BDNF protein, human
7171WSG8A2
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
46-51Informations de copyright
© 2019 The Authors. Neuropsychopharmacology Reports published by John Wiley & Sons Australia, Ltd on behalf of the Japanese Society of Neuropsycho Pharmacology.
Références
J Clin Psychiatry. 2005;66 Suppl 3:12-9
pubmed: 15762830
J Affect Disord. 2015 Aug 15;182:50-6
pubmed: 25973783
Proc Natl Acad Sci U S A. 1996 Aug 6;93(16):8455-9
pubmed: 8710892
Am J Med Genet B Neuropsychiatr Genet. 2014 Apr;165B(3):217-22
pubmed: 24677591
Am J Med Genet B Neuropsychiatr Genet. 2014 Jun;165B(4):365-72
pubmed: 24804643
J Affect Disord. 2014 Sep;166:193-200
pubmed: 25012431
BMC Med Genet. 2017 Oct 23;18(1):117
pubmed: 29061165
Psychopharmacology (Berl). 2001 Oct;158(1):100-6
pubmed: 11685390
Int J Neuropsychopharmacol. 2008 Dec;11(8):1169-80
pubmed: 18752720
J Clin Psychiatry. 2002 Oct;63(10):942-7
pubmed: 12416605
Mol Psychiatry. 2009 Jan;14(1):51-9
pubmed: 17925795
Cortex. 2013 Nov-Dec;49(10):2700-10
pubmed: 23517654
Gene. 2013 Mar 10;516(2):285-90
pubmed: 23266638
Arch Gen Psychiatry. 1997 Jul;54(7):597-606
pubmed: 9236543
J Clin Psychiatry. 1998;59 Suppl 6:13-9; discussion 20
pubmed: 9674932
Neuropsychopharmacol Rep. 2020 Mar;40(1):46-51
pubmed: 31769621
Neurosci Biobehav Rev. 2007;31(6):920-31
pubmed: 17499358
Transl Psychiatry. 2016 May 31;6(5):e824
pubmed: 27244233
Neurogenetics. 2014 May;15(2):117-27
pubmed: 24643514
J Neurosci. 2011 Mar 2;31(9):3295-308
pubmed: 21368041
J Neurochem. 1999 Mar;72(3):1327-30
pubmed: 10037507
Br J Psychiatry. 1978 Nov;133:429-35
pubmed: 728692
J Clin Psychiatry. 2003 Jul;64(7):841-6
pubmed: 12934987
Mol Psychiatry. 2016 Jan;21(1):89-93
pubmed: 25560756
Arch Gen Psychiatry. 2012 Dec;69(12):1238-46
pubmed: 23044507
BMC Genet. 2015 Mar 15;16:27
pubmed: 25887117
CNS Drugs. 2009;23(3):225-40
pubmed: 19320531
World J Biol Psychiatry. 2002 Jul;3(3):115-24
pubmed: 12478876
Microarrays (Basel). 2014 Feb 28;3(1):52-71
pubmed: 27605030
N Engl J Med. 2008 Aug 28;359(9):918-27
pubmed: 18753648
J Neurosci. 1995 Nov;15(11):7539-47
pubmed: 7472505
Science. 2003 Oct 31;302(5646):885-9
pubmed: 14593183
Am J Psychiatry. 2008 Oct;165(10):1316-25
pubmed: 18381903
Mol Psychiatry. 2000 Nov;5(6):578-93
pubmed: 11126389
Arch Gen Psychiatry. 2002 Jan;59(1):62-9
pubmed: 11779284
Genomics. 1994 Nov 1;24(1):69-77
pubmed: 7896291